VivoSeq
Other

Paclitaxel

0

Pipeline Programs↗

9

Active Trials↗

11

Companies Involved↗

Paclitaxel is an early-stage landscape with 0 programs across 11 companies. The most active players are Gynecologic Oncology Group, AstraZeneca, OncoMed Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

65/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalO

OncoMed Pharmaceuticals, Inc.

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalS

Sichuan Baili Pharmaceutical Co., Ltd.

0 programs

PreclinicalS

Shandong Luye Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

62

clinical trials

Completed28 · 45%
Terminated12 · 19%
Unknown status10 · 16%
Active, not recruiting4 · 6%
Recruiting3 · 5%
Withdrawn3 · 5%
Other2 · 3%

Clinical Trials

Trial Activity

62 trials

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04449549·82 enrolled
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Recruiting·FFudan University·Phase 2·NCT06684327·100 enrolled
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Recruiting·HHallym University Medical Center·Phase 1/2·NCT05439993·42 enrolled
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05054439·42 enrolled
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
Active, not recruiting·—·N/A·NCT06481553·480 enrolled
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05554341·40 enrolled
Onvansertib + Paclitaxel In TNBC
Active, not recruiting·—·Phase 1/2·NCT05383196·50 enrolled
GIST Oral Paclitaxel(Liporaxel)
Not yet recruiting·—·Phase 2·NCT06326346·28 enrolled
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Not yet recruiting·PPeking University·Phase 2·NCT06222944·90 enrolled
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Completed·NNYU Langone Health·Phase 2·NCT02280252·69 enrolled
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Completed·LLaekna Limited·Phase 2·NCT04374630·150 enrolled
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
Completed·—·N/A·NCT02145065·66 enrolled
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Completed·—·Phase 2·NCT01853748·512 enrolled
A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Completed·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT02193633·90 enrolled
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
Completed·—·Phase 2·NCT01637077·46 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)